Read our latest updates & insights

On 10 December 2025, Zydus Lifesciences announced the Indian launch of Zyrifa™ (denosumab 120mg SC), biosimilar to Amgen’s Xgeva® (denosumab).

The launch of Zydus’ denosumab biosimilar in India follows a flurry of European denosumab biosimilar launches on 1-2 Decembe...

On 9 December 2025, Formycon and Zydus Lifesciences announced that they have entered into an exclusive licensing and supply agreement for the commercialisation of FYB206, biosimilar to MSD’s Keytruda® (pembrolizumab), in the US and Canada.

Under the agreement, Formyc...

On 8 December 2025, Celltrion announced that it intends to expand its biosimilar pipeline by “internalising” hyaluronidase-based subcutaneous delivery (SC) formulation technology.  According to Celltrion, its SC technology involves temporarily decomposing hyaluronic acid pr...

On 8 December 2025, GxP News reported that Russia’s Binnopharm Group and China’s Mabwell have signed a MOU in relation to localising the production of Mabwell’s biosimilar to Regeneron/Sanofi’s Dupixent® (dupilumab) in Russia and the EAEU.

The two companies have prev...

On 6 December 2025, Biocon Limited announced that Biocon Biologics will be integrated into it, becoming a wholly owned subsidiary of the company upon completion of the transaction, expected to occur by 31 March 2026.

Under the proposed transaction, Biocon Limited wil...

On 5 December 2025, Korea’s HIT News reported that Samsung Bioepis has successfully overturned a preliminary injunction granted to Regeneron and Bayer which was preventing Korean sales of Samsung Bioepis’ Afilivu® (SB15), biosimilar to Regeneron/Bayer’s Eylea® (aflibercept)...